Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Supine Therapeutics Co. Ltd. is currently active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This action is being processed within 1 distinct art unit, indicating a specific technical focus for the company's current biotechnology filings. The concentration in 1 distinct art units suggests a targeted application of their therapeutic technology within a specialized examination group. This singular point of engagement allows for a highly specialized prosecution strategy for the company's current intellectual property.
The prosecution is managed by 1 distinct examiners, with SINGH, SATYENDRA K identified as the busiest examiner. SINGH, SATYENDRA K is responsible for 1 busiest examiner pending office action, which represents the entirety of the company's current pending workload. This creates a singular channel for negotiation and response between the company and the USPTO. Having 1 pending office action and 1 distinct examiners simplifies the strategic planning for the portfolio, as there is no need to coordinate between different examiner preferences.
Practitioners can focus exclusively on the requirements and examination style of SINGH, SATYENDRA K within the Biotechnology & Pharmaceuticals field. This focused approach minimizes the need for multi-examiner coordination and allows for a concentrated effort on the 1 distinct art units involved. With 1 busiest examiner pending, the applicant can anticipate a consistent review process for their current filing. The 1 distinct examiners currently assigned ensures that the company's intellectual property strategy remains unified and focused on its core therapeutic objectives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SINGH, SATYENDRA K | 1 | 61.5% | +67.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18780922 | METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SPINAL CORD INJURY | SINGH, SATYENDRA K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18780922 | METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SPINAL CORD INJURY | SINGH, SATYENDRA K | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18780922 | METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SPINAL CORD INJURY | SINGH, SATYENDRA K | 1657 | §102§103§112Other | Non-Final OA | — | Pending | Jul 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSupine Therapeutics Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Satyendra K Singh has the most, with 1 of Supine Therapeutics Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
